Previous work has indicated recreational use of methylenedioxymethamphetamine (MDMA or ecstasy) is associated with elevated scores on self-report measures of depression. We sought to examine the long-term effects of consumption on depression in a group of individuals who had consumed large quantities of the drug in the past, but were now leading relatively drug free lives. Respondents to this study (n = 29) had consumed an average of 1.5 ecstasy tablets in the last month, 8.4 in the last 6 months and 23.3 in the last 12 months. The estimated total consumed was 527 tablets, indicating that these respondents were indeed former chronic users of the drug. None of the respondents had consumed ecstasy in the last 14 days. Levels of depression (Beck's Depression Inventory) were significantly (p < 0.01) elevated compared to a matched non-drug using control group. Within the group of former chronic users, these levels of depression were not significantly affected by current use of alcohol, cannabis or amphetamine, but were positively correlated with an external locus of control (p< 0.05), infrequent but severe- (p< 0.05) and frequent but mild- (p< 0.005) self-report measures of life stress. Multiple regression indicated that levels of frequent but mild life stress (p< 0.005) and the quantity of ecstasy tablets respondents consumed over a 12-h period (p< 0.05) were the only variables that were significant predictors of self-reported levels of depression. The results of this study indicate that former chronic ecstasy users report higher levels of depression than their matched controls.
Battaglia G, Brooks B P, Kulsakdinun C, De Souza E B (1988) Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol149: 159–163
2.
Beck A T, Ward C H, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry4: 53–63
3.
Benazzi F, Mazzoli M (1991) Psychiatric illness associated with ecstasy. Lancet338: 1520-1520
4.
Cole J, Whitehead D L, Sumnall H R (1999) Increased OCD symptomatology may be associated with recreational MDMA (‘ecstasy’) use in females. J Psychopharmacol13: OR17-OR17
5.
Curran H V, Travill R A (1997) Mood and cognitive effects of +3,4-methylenedioxy-methamphetamine (MDMA, ‘ecstasy’): weekend ‘high’ followed by midweek low. Addiction92: 821–831
6.
Fischer C, Hatzidimitriou G, Wlos J, Katz J, Ricaurte G (1995) Reorganisation of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/–) 3,4-methylene-dioxy-meth-amphetamine (MDMA, ‘ecstasy’). J Neurosci15: 5476–5485
7.
Gamma A, Frei E, Lehmann D, Pascual-Marqui RD, Hell D, Vollenweider FX (2000) Mood state and brain electric activity in ecstasy users. Neuroreport11: 157–162
8.
Gerra G, Zaimovic A, Giucastro G, Maestri D, Monica C, Sartori R, Caccavari R, Delsignore, R (1998) Serotonergic function after (+/–) 3,4-methylene-dioxymethamphetamine (‘ecstasy’) in humans. Int Clin Psychopharmacol13: 1–9
9.
Gerra G, Zaimovic A, Ferri M, Zambelli U, Timpano M, Neri E, Marzocchi GF, Delsignore R, Brambilla F (2000) Long-lasting effects of (±)3,4-methlene-dioxymethamphetamine (ecstasy) on serotonin system function in humans. Biol Psychiatry47: 127–136
10.
Hammen L C, Cochran S D (1981) Cognitive correlates of life stress and depression in college students. J Abnorm Psychol90: 23–27
11.
Hammen L C, Marks T, Mayol A, deMayo R (1985) Depressive self-schemas, life stress, and vulnerability to depression. J Abnorm Psychol94: 308–319
12.
Henry J A (1992) Ecstasy and the dance of death. Br Med J305: 5–6
13.
HMSO (1971) Misuse of Drugs Act 1971. C. 38. Her Majesty's Stationery Office, London
14.
Holmes T H, Rahe R H (1967) The social readjustment rating scale. J Psychosom Res11: 213–218
15.
Kanner A D, Coyne J C, Schaefer C, Lazarus R S (1981) Comparison of two modes of stress measurement: daily hassles and uplifts versus major life events. J Behav Med4: 1–39
16.
McCann U D, Ricaurte G A (1991) Lasting neuropsychiatric sequelae of methylene-dioxy-meth-amphetamine (‘ecstasy’) in recreational users. J Clin Psychopharmacol11: 302–305
17.
McCann U D, Ridenour B S, Shaham Y, Ricaurte G A (1994) Serotonin neurotoxicity after 3,4-methylene-dioxy-meth-amphetamine (MDMA; ‘ecstasy’): a controlled study in humans. Neuropsychopharmacology10: 129–138
18.
McCann U D, Szabo Z, Scheffel U, Dannals R F, Ricaurte G A (1998) Positron emission tomographic evidence of toxic effect of MDMA (‘ecstasy’) on brain serotonin neurons in human beings. Lancet352: 1433–1437
19.
McCann U D, Mertl M, Eligulashvili V, Ricaurte G A (1999) Cognitive performance in (+/–) 3,4-methylenedioxymetham-phetamine (MDMA, ‘ecstasy’) users: a controlled study. Psychopharmacology143: 417–425
20.
McGuire P K, Cope H, Fahy T (1994) Diversity of psychopathology associated with use of 3–4 methylene-dioxy-meth-amphetamine (‘ecstasy’). Br J Psychiatry16: 391–395
21.
McKenna D S, Peroutka S J (1990) Neurochemistry and neurotoxicity of 3,4-methylene-dioxy-meth-amphetamine (MDMA, ‘ecstasy’). J Neurochem54: 14–22
22.
Montgomery A M J, Esposito G, Townsend C (1999) Recreational use of MDMA (ecstasy) is associated with increased anxiety and depression scores. J Psychopharmacol13: P133-P133
23.
Morgan M J (1998) Recreational use of ‘ecstasy’ (MDMA) is associated with elevated impulsivity. Neuropsycho-pharmacology19: 252–264
24.
Morgan M J (1999) Memory deficits associated with recreational use of ‘ecstasy’. Psychopharmacology141: 30–36
25.
Parrott A C (1998) Emotional and cognitive effects of MDMA (‘ecstasy’): the psychological perspective. J Psychopharmacol12: 99–100
26.
Parrott A C, Lasky L (1998) Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology139: 261–268
27.
Parrott A C, Lees A, Garnham N J, Jones M, Wesnes K (1998) Cognitive performance in recreational users of MDMA or ‘ecstasy’: evidence for memory deficits. J Psychopharmacol12: 79–83
28.
Parrott A C, Sisk E, Turner J J D (2000) Psychobiological problems in heavy ‘ecstasy’ (MDMA) polydrug users. Drug Alcohol Depend60: 105–110
29.
Paykel E S (1979) Recent life events in the development of the depressive disorders. In Depue R A (eds), The psychobiology of the depressive disorders: implications for the depressive disorders. Academic Press, San Diego
30.
Peroutka S J, Newman H, Harris H (1988) Subjective effects of 3,4-methylene-dioxy-meth-amphetamine in recreational users. Neuropsychopharmacology1: 273–277
31.
Rahe R H, Meyer T H, Smith M, Kjaer G, Holmes T H (1964) Social stress and illness onset. J Psychosom Res8: 35-35
32.
Rahe R H, Lundberg U, Bennet L, Theorell T (1971) The social readjustment rating scale: a comparative study of Swedes and Americans. J Psychosom Res15: 241–249
33.
Ricaurte G A, Forno L S, Wilson M A, DeLanney L E, Irwin I, Langston J W (1988) 3,4-methylene-dioxy-meth-amphetamine (MDMA) selectively, damages central serotonergic neurons in non-human primates. J Am Med Assoc260: 51–55
34.
Rotter J B (1966) Generalised expectancies for internal versus external control of reinforcement. Psychological monographs: applied and general 80. Whole no. 609, pp. 1–28
35.
Royal Pharmaceutical Society (1999) Martindale: the extra pharmacopeia, 31st edn.Royal Pharmaceutical Society, London
36.
Schifano F, Magni G (1994) MDMA (‘ecstasy’) abuse: psycho-pathological features and a craving for chocolate: a case series. Biol Psychiatry36: 763–767
37.
Schifano F, Di Furia L, Forza C, Minicuci N, Bricolo R (1998) MDMA (‘ecstasy’) consumption in the context of polydrug abuse: a report on 150 patients Drug Alcohol Depend52: 85–90
38.
Semple D M, Ebmeier K P, Glabus M F, Ocarroll R E, Johnstone E C (1999) Reduced in vivo binding to the serotonin transporter in cerebral cortex of MDMA (‘ecstasy’). Br J Psychiatry175: 63–69
39.
Solowij N, Hall W, Lee N (1992) Recreational MDMA use in Sydney: a profile of ‘ecstasy’ users and their experiences with the drug. Br J Addict87: 1161–1172
40.
Weinberger M, Hiner SL, Tierney W M (1987) In support of Hassles as a measure of stress in predicting health outcomes. J Behav Med10: 19–31
41.
Winstock A R (1991) Chronic paranoid psychosis after misuse of MDMA (letter; comment). Br Med J302: 1150–1151
